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Abstract
Background: Gastrointestinal dysfunction and gut microbial composition disturbances have been widely reported
in autism spectrum disorder (ASD). This study examines whether gut microbiome disturbances are present in the
BTBRT + tf/j (BTBR) mouse model of ASD and if the ketogenic diet, a diet previously shown to elicit therapeutic
benefit in this mouse model, is capable of altering the profile.
Findings: Juvenile male C57BL/6 (B6) and BTBR mice were fed a standard chow (CH, 13 % kcal fat) or ketogenic diet
(KD, 75 % kcal fat) for 10–14 days. Following diets, fecal and cecal samples were collected for analysis. Main findings are
as follows: (1) gut microbiota compositions of cecal and fecal samples were altered in BTBR compared to control mice,
indicating that this model may be of utility in understanding gut-brain interactions in ASD; (2) KD consumption caused
an anti-microbial-like effect by significantly decreasing total host bacterial abundance in cecal and fecal matter; (3)
specific to BTBR animals, the KD counteracted the common ASD phenotype of a low Firmicutes to Bacteroidetes ratio
in both sample types; and (4) the KD reversed elevated Akkermansia muciniphila content in the cecal and fecal matter
of BTBR animals.
Conclusions: Results indicate that consumption of a KD likely triggers reductions in total gut microbial counts and
compositional remodeling in the BTBR mouse. These findings may explain, in part, the ability of a KD to mitigate some
of the neurological symptoms associated with ASD in an animal model.
Keywords: Ketogenic diet, Gut microbiome, Autism spectrum disorder, BTBR mouse
Abbreviations: ANOVA, Analysis of variance; ASD, Autism spectrum disorder; CH, Control diet; KD, Ketogenic diet;
PLS-DA, Partial least squares discriminant analysis; SCFAs, Short-chain fatty acids; VIP, Variable importance of projection
Introduction
Autism spectrum disorder (ASD) encompasses several
neurodevelopmental disorders in which seizures and
gastrointestinal (GI) dysfunction exist as symptoms [1, 2].
Residing within the GI tract, the gut microbiome is a
vastly diverse ecosystem comprised of trillions of bacteria
and other microorganisms [3]. Yielding a metabolic cap-
acity of ~100-fold greater than the human liver, these bac-
teria have been implicated in altering host metabolism
and immune function [3, 4]. Recent research has also
demonstrated alterations in the microbial profile of both a
valproic acid-exposed animal model of ASD [5] and pa-
tients with ASD compared to controls [1, 2].
The BTBRT+ tf/j (BTBR) mouse mimics the behavioral
phenotype associated with ASD, although it lacks spon-
taneous seizure activity [6, 7]. The ketogenic diet
(KD), which has been implemented as a treatment to
pharmacologically resistant epilepsy since the early twenti-
eth century [6], has been shown to improve the core
symptoms of ASD in BTBR animals [6]. This work repre-
sents the first successful use of a dietary therapy to coun-
teract communication defects, repetitive behaviors, and
impairments in sociability in a mouse model of ASD.
Comprising of a high proportion of fat, adequate protein,
and low carbohydrates, the KD causes a drastic shift in
host metabolism by mimicking the fasting state and
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promoting ketone body production and utilization. Al-
though the KD primarily impacts neural tissue [8], the im-
pact of such radical metabolic changes on the gut
microbiome has yet to be examined.
Research investigating both brain and gut function has
demonstrated that both tissues have various degrees of in-
volvement in ASD progression [5, 9]. A recent unifying
theory termed the “gut-brain axis” outlines the interactions
between the brain and microbiome, suggesting a possible
connection in ASD [9, 10]. This research proposes that
disruption to gut microbiota composition or diversity can
modulate behavior and neural biochemistry. Therefore,
the aim of this study was to examine the impact of a KD
on the gut microbiota of a mouse model of ASD.
Methods
Animals and dietary interventions
All experimental protocols were in compliance with the
ethical standards approved by the University of Calgary
Animal Care and Use Committee. Juvenile male C57BL/6
(B6) and BTBRT+ tf/j mice (n = 21 and 25, respectively)
were age-matched to 5 weeks of age before being ran-
domly selected for implementation of a standard chow
(CH, 13 % kcal fat) or ketogenic diet (KD, 75 % kcal fat;
Bio-Serv F3666, Frenchtown, USA) for 10–14 days. The
time point of 7 weeks of age for both B6 and BTBR mice
was established to ensure both cohorts were post-pubertal
in development [11]. Prior to sacrifice, the animals were
housed in a humidity-controlled room with a 12-h light/
dark zeitgeber cycle and were fed ad libitum. Following
10–14 days of dietary intervention, the mice were sacri-
ficed by cervical dislocation. At the time of sacrifice, the
animals were 7 weeks of age.
Behavioral analysis
Previously published work on the BTBR mouse has exam-
ined the impact of the KD on several behavioral measures
at similar ages as the mice in the present study [12].
Briefly, self-directed repetitive behavior (self-grooming)
was quantified in the three-chamber sociability test, and
communication was assessed by social transmission of a
food preference [6]. This data has been re-reported and is
shown to provide a frame of reference for the present
work on the gut microbiome in relation to the diet.
DNA extraction and qRT-PCR analysis
Fresh fecal samples were collected prior to sacrifice and
cecal contents collected posthumously. All samples were
stored at −80 °C until analysis. Using ~250 mg of fecal/
cecal matter, total DNA was extracted and quantified as
previously described [13]. Microbial profiling was con-
ducted using an iCycler (BioRad, Hercules, USA) as previ-
ously reported [13]. Standard curves were normalized to
the copy number of 16S ribosomal RNA (rRNA) genes
using reference strain genome size and 16S rRNA gene
copy number values obtained from the following reference
[14]. Data are expressed as 16S rRNA gene copies/mg
cecal or fecal matter. Group-specific primers are shown in
Additional file 1: Table S1 and referenced in previously
published work [13]. All baseline animal and transformed
gut microbiota data have been previously published [15],
and they are included here to provide a frame of reference
for the autism-related data. Previously published work ex-
amines the mathematical relationship between specific gut
microbes and serum metabolomics and not ASD.
Statistical analysis
Statistical analysis was performed using IBM SPSS Sta-
tistics for Windows, version 20.0. Data are expressed as
mean ± SEM. Differences between the genotype and diet
were determined by analysis of variance (ANOVA),
followed by Tukey’s post hoc test where p < 0.05 was
considered to be significant. Microbial data was normal-
ized and uploaded into MetaboAnalyst 3.0 for modeling
using partial least squares discriminant analysis (PLS-
DA). Variable importance of projection (VIP) scores
were assessed in order to rank each microbial group for
their degree of discrimination within the model.
Findings
The BTBR mouse exhibits many behavioral phenotypes
relevant to ASD including impaired vocalizations and
social interactions [12, 16]. Previous work investigating
the impact of the KD on the BTBR demonstrates the
diet to improve sociability and communication of food
preference while decreasing self-directed repetitive be-
haviors [6]. The mechanism(s) mediating these benefits
are presently unknown, but many involve the gut micro-
biota communication. The objective of the present study
was to examine the impact of a KD on the gut micro-
biota of a mouse model of ASD.
The major findings of this study are as follows: (1) gut
microbiota composition of cecal and fecal samples were
altered in BTBR compared to control mice, indicating
that this model may be of utility in understanding gut-
brain interactions in ASD; (2) KD consumption caused
an “anti-microbial”-like effect by significantly decreasing
total host bacterial abundance in cecal and fecal matter;
(3) specific to BTBR animals, the KD counteracted the
common ASD phenotype of a low Firmicutes to Bacter-
oidetes ratio in both cecal and fecal matter; and (4) the
KD reversed the elevated Akkermansia muciniphila con-
tent in the cecal and fecal matter of BTBR animals.
Our results identified distinct differences in animal
mass between control and BTBR animals (Table 1). Fur-
ther differences between genotype were noted following
16S rRNA microbial profiling of cecal and fecal samples.
Examination of the data employing multivariate analysis
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discerned that our control (B6) and BTBR mice had dis-
similar cecal and fecal microbial profiles (Fig. 1a–d and
Table 2). The top three metabolites responsible for driv-
ing the separation of groups included A. muciniphila,
Methanobrevibacter spp., and Roseburia spp. in the cecal
samples and A. muciniphila, Enterobacteriaceae, and
Lactobacillus in the fecal samples.
Cecal and fecal tissues were both assessed in the present
study as research indicates that microbial abundance and
diversity are directly related to the physiological role of each
segment of the GI tract [17]. Supporting previous work,
our data shows an increase in total microbial content fur-
ther down the GI tract and an increase in the obligate
anaerobes Bacteroidetes (Bacteroides/Prevotella spp.) in
fecal tissues [17]. However, with the exception of Entero-
bacteriaceae, directional changes occurring with the KD
were generally conserved between these two sampling sites.
Examination of our data show several alterations in
fecal gut microbiota of BTBR mice that are observed in
patients with ASD, including elevated Clostridium clus-
ter XI [18], decreased Firmicutes (Clostridium coccoides,
Clostridium leptum, Clostridium clusters XI and I, Rose-
buria spp., and Lactobacillus spp.) [2] and increased
Bacteroidetes [1]. Taken together, our results indicate
that the BTBR mouse model may provide insight into
the role of gut-brain interactions in ASD and that it may
be useful in testing the impact of interventions such as
pre- and probiotic administration on the disease.
Results of both cecal and fecal analysis showed a
significant decline in total bacterial content upon im-
plementation of the KD, in both animal genotypes
(Fig. 1a, b). Interestingly, the KD decreased total cecal
and fecal microbes in BTBR animals by a mean of 78
and 28 %, respectively. These are explained by the gut
microbiota’s primary responsibility to degrade un-
digested carbohydrates, which are substantially dimin-
ished in the KD [19]. Consistent with this, short-term
administration of vancomycin, a broad-spectrum oral
antibiotic, has been reported to improve behavioral
symptoms of ASD in young boys [20]. As vancomycin
is unable to be absorbed and has no interaction with
the central nervous system, the resulting behavioral
improvements are thought to involve gut microbiome-
drug interactions [21].
Although the gut microbiome is comprised of hundreds
of discernible species, approximately 90 % of measured
16S rRNA sequences belong to the Firmicutes or Bacter-
oidetes phyla [19]. While estimations of complete micro-
bial diversity remain a limitation of 16S profiling, a
targeted approach was employed to identify commonly
abundant microbial species. Interestingly, the decrease in
Firmicutes and increase in Bacteroidetes across both cecal
and fecal matter were mitigated in BTBR animals fed a
KD (Table 2). The Firmicutes phylum is comprised of sev-
eral classes of gram-positive bacteria which include Clos-
tridia [22]. Clostridia can be further divided into
approximately 20 clusters including the abundant C. coc-
coides and C. leptum [23]. C. coccoides and C. leptum are
saccharolytic bacteria that generate short-chain fatty acids
(SCFAs) [23]. Recent research suggests that the SCFAs bu-
tyrate and propionate actively communicate with the brain
[24]. Our data shows a relative two- to threefold increase
in the known SCFA generating C. coccoides and C. leptum
populations, respectively, when cecal and fecal samples of
BTBR-ketogenic animals are compared to all other groups
(Table 2). The ability to alter the ASD microbial pheno-
type in the BTBR mouse through dietary manipulation
may elucidate the mechanism of action connecting KD
and its capacity to improve ASD behavioral symptoms.
A variety of neurological disorders, including ASD, is as-
sociated with various GI symptoms, including abdominal
pain, inflammation, and impaired gastric motility [23].
These symptoms are thought to be partially attributed to
the maintenance of the mucosa, a multi-layered tissue
comprising the innermost layer of the GI tract. Comprom-
ising the integrity of this physical barrier results in intes-
tinal permeability and has been highlighted in clinical
cases of ASD [9, 25]. The mucin protein family is the pre-
dominant source of proteins contributing to mucus secre-
tions from the epithelial layer of the mucosa [26]. Within
the GI lumen resides the mucin-degrading bacterium A.
muciniphila—the predominant representative of the Ver-
rucomicrobia phylum within the GI tract [27]. Responsible
for maintaining homeostasis of mucus secretions, research
suggests that diminished gut microbial diversity [28], mu-
cosal infiltration [27], and ASD [1, 2] are linked to in-
creased A. muciniphila. Our results indicate that BTBR
animals fed a chow diet have significantly elevated A.
muciniphila in both cecal and fecal matter (Table 2). The
source or underlying cause of this elevation is not known.
However, the ketogenic diet resulted in a normalization of
A. muciniphila bacteria in BTBR mice, resulting in similar
levels to those found in control (B6), chow-fed animals. In
fact, this bacterial species was the primary bacteria driving
the calculated multivariate discrimination in both our
cecal and fecal samples (Fig. 1e, f ).
Table 1 Animal characteristics
B6 BTBR
Chow Ketogenic Chow Ketogenic
Mass (g) 18.4 ± 0.8a 10.5 ± 0.3b 28.6 ± 1.3c 15.9 ± 1.0a
Blood glucose (mmol/L) 10.4 ± 0.6a 4.3 ± 0.5b 7.8 ± 0.3c 3.7 ± 0.5b
Blood ketones (mmol/L) 0.9 ± 0.1a 5.1 ± 0.8b 0.9 ± 0.1a 5.1 ± 0.8b
Age-matched B6 and BTBR mice were sacrificed following 10–14 days of either
chow or ketogenic feeding. All characteristics were assessed prior to sacrifice.
Data are mean ± SEM (B6-chow, B6-ketogenic, BTBR-chow, and BTBR-ketogenic;
n = 11, 10, 15, and 10, respectively). p < 0.01 if superscripts do not share a letter
(a, b, and c)
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Fig. 1 (See legend on next page.)
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In summary, this study demonstrates that KD con-
sumption triggers gut microbiota remodeling in an
animal model of ASD. These findings may provide
insight into the therapeutic potential of KD manipula-
tion by influencing gut microbial composition. Due to
the paucity of research examining the role of the
microbiome in KD therapy, we suggest further inves-
tigations into the complex interplay between the gut
microbiome and the brain relevant to ASD and other
neurological disorders.
(See figure on previous page.)
Fig. 1 Assessment of total microbial content, partial least squares discriminant analysis (PLS-DA), and variable importance of projection (VIP) scores for
relative bacterial abundance. Descriptive comparisons of total microbial content, score plots of PLS-DA, and VIP scores for both cecal and fecal matter
are presented. a Total bacterial species composition measured from cecal matter. b Total bacterial species composition measured from fecal matter.
c PLS-DA score plot for cecal matter showing model discrimination between each genotype. d PLS-DA score plot for fecal matter showing model
discrimination between each genotype. e Cecal VIP plot indicating the most discriminating bacteria in descending order of importance. f Fecal VIP plot
indicating the most discriminating bacteria in descending order of importance. Statistical comparisons between genotype and diet were determined
by ANOVA, followed by Tukey’s post hoc test. PLS-DA and VIP scores were assessed using MetaboAnalyst 3.0. Ellipses represent 95 % confidence
intervals for each individual group on PLS-DA plots with Q2 and R2 values being used to assess the robustness of the model and the amount of variation
represented by the principal components, respectively. VIP scores reflect the degree of importance of a bacteria, with values >1.0 seen as driving the
calculated discrimination. All data were collected using qRT-PCR and are presented as mean 16S rRNA gene copies/mg of corresponding tissue ± SEM
(CC, B6-chow; CK, B6-ketogenic; BC, BTBR-chow; and BK, BTBR-ketogenic; n= 11, 10, 15, and 10, respectively). p< 0.01 if values do not share a superscript letter.
An adapted version of this table has been previously published. Reprinted with permission of the American Chemical Society, Copyright 2016
Table 2 Microbiota composition in cecal and fecal samples from B6 and BTBR mice following chow or ketogenic feeding
B6 BTBR
Chow Ketogenic Chow Ketogenic
Cecal microbes (×1000) Akkermansia muciniphila 1.1 ± 0.1a 0.3 ± 0.04b 1011 ± 153c 0.2 ± 0.02b
Bacteroides/Prevotella spp. 7028 ± 611ab 5044 ± 1114a 9233 ± 1211b 709 ± 317c
Bifidobacterium spp. 6132 ± 1071a 17.6 ± 4.8b 381 ± 95c 5.6 ± 0.9d
Clostridium cluster I 24.6 ± 2.2a 9.3 ± 1.7b 13.9 ± 1.7c 6.2 ± 0.7b
Clostridium cluster XI 1.4 ± 0.1a 3.7 ± 0.8b 1.0 ± 0.09c 2.7 ± 0.3b
Clostridium coccoides 53,223 ± 4428a 17,128 ± 4253b 46,568 ± 3885a 11,157 ± 2451b
Clostridium leptum 4959 ± 811ab 2668 ± 690ac 6150 ± 612b 1570 ± 281c
Enterobacteriaceae 257 ± 42a 70 ± 12b 77 ± 7.9b 36 ± 4.7c
Total Firmicutes 61,819 ± 4641a 19,874 ± 4290b 57,015 ± 4086a 12,795 ± 2602b
Lactobacillus spp. 3609 ± 1078a 65 ± 31b 4279 ± 790a 59 ± 36b
Methanobrevibacter spp. 2.6 ± 0.5a 3.4 ± 0.2b 10 ± 0.9c 2.9 ± 0.4ab
Roseburia spp. 2.4 ± 0.3a 0.7 ± 0.08b 3.3 ± 0.3a 0.5 ± 0.1b
Firmicutes/Bacteroidetes ratio 9.4 ± 1.0a 4.6 ± 1.2a 6.9 ± 0.7a 32.5 ± 5.8b
Fecal microbes (×1000) Akkermansia muciniphila 0.2 ± 0.02ab 0.3 ± 0.06ac 1392 ± 223d 0.2 ± 0.03bc
Bacteroides/Prevotella spp. 11,734 ± 1128a 31,189 ± 6810b 22,562 ± 3294b 3654 ± 903c
Bifidobacterium spp. 10,414 ± 999a 120 ± 27b 951 ± 229c 22.6 ± 5.2d
Clostridium cluster I 5.6 ± 0.4a 12.7 ± 2.0bc 18.0 ± 2.7bd 15.3 ± 2.4cd
Clostridium cluster XI 11.6 ± 1.1ab 8.2 ± 1.4ac 4.4 ± 1.3d 10.6 ± 1.5bc
Clostridium coccoides 26,467 ± 4814a 20,859 ± 3938a 36,587 ± 4428a 37,019 ± 7867a
Clostridium leptum 2879 ± 613ab 3015 ± 594a 3956 ± 364bc 7245 ± 1508c
Enterobacteriaceae 253 ± 25ab 633 ± 161ac 116 ± 9.5d 419 ± 112bc
Total Firmicutes 37,399 ± 5318a 24,121 ± 3998b 49,118 ± 4672a 44,782 ± 7907a
Lactobacillus spp. 8031 ± 1573a 225 ± 80b 8548 ± 1535a 492 ± 134b
Methanobrevibacter spp. 9.0 ± 0.7a 0.7 ± 0.1b 5.7 ± 1.9c 0.8 ± 0.1b
Roseburia spp. 5.3 ± 0.6a 1.3 ± 0.2b 5.3 ± 0.9a 0.9 ± 0.1b
Firmicutes/Bacteroidetes ratio 3.5 ± 0.7a 1.2 ± 0.3a 2.4 ± 0.2a 13 ± 1.8b
Total Firmicutes (Clostridium coccoides, Clostridium leptum, Clostridium clusters XI and I, Roseburia spp., and Lactobacillus spp.) and Bacteroidetes (Bacteroides/
Prevotella spp.). Data are mean 16S rRNA gene copies/mg cecal or fecal matter ± SEM (n = 11, 10, 15, and 10 respectively). p < 0.05 if values do not share a
superscript letter
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Additional file 1: Table S1. Gut microbial group-specific primers and
genomic DNA standards for qRT-PCR. (DOC 48 kb)
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